Skip to main content
Fig. 3 | Antimicrobial Resistance & Infection Control

Fig. 3

From: Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a retrospective cohort study

Fig. 3

Antibiotic use of total study population per admission day. *Other combination therapy: a combination of beta-lactam antibiotics, combination of beta-lactam antibiotic with macrolide/quinolone/glycopeptide/cotrimoxazole/metronidazole or combinations of three different antibiotic classes. **Other monotherapy: other beta-lactam antibiotics (e.g. flucloxacillin or ceftazidime) or any of the other antibiotic classes (e.g. nitrofurantoin, cotrimoxazole)

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us